By Keegan Hamilton
By Albert Samaha
By Village Voice staff
By Tessa Stuart
By Albert Samaha
By Steve Weinstein
By Devon Maloney
By Tessa Stuart
Attention corporate America: the logo and likeness of USA Today, the nation's second-largest circulation newspaper, are for sale.
That disturbing fact became clear in late June, when USA Todaypublished a separate, two-page version of the paper for pharmaceutical giant Glaxo Wellcome.
As shown in the illustration, the "special promotional edition" used USA Today's trademarked logo, typefaces, colors, and layouts. Each "article" was actually a piece of marketing information about Glaxo's AIDS remedies, written by Glaxo staff.
Almost all the paper's phony news stories quote Glaxo officials as sources. One of the front-page "articles" actually refered to the edition as "this page of USA Today," thereby encouraging readers to accept the ad copy as if it were the newspaper.
When informed of these promotional editions, many journalists, including some at USA Today, were appalled. "You don't mislead readers, and selling the logo is probably the most misleading thing you can do," says Eugene Roberts, the veteran former high-level editor of the Philadelphia Inquirerand The New York Times, now teaching at the University of Maryland. "It puts a highly visible stamp on the page and says to the reader, 'This is today's newspaper.' "
USA Todayspokesperson Steve Anderson insists that the papers "went to great pains" to mark the editions as promotional. But the slash across the top was so small--seven-point type, compared to the logo's 72-point type--that, according to Glaxo Wellcome spokesperson Mary Fay Dark, many readers read quite far into the "paper" before realizing the entire edition was an ad.
Roberts dismisses the attempt at a disclaimer. "If you have to go to fine print to find out it isn't the real paper, that's a problem," he tells my Voice colleague Mark Schoofs. "You shouldn't have to read a newspaper like an insurance policy."
The Glaxo USA Today was distributed last month at the World AIDS Conference in Geneva. Some 6000 copies were wrapped around the European edition of the paper and delivered to conference attendees at major Geneva hotels.
This was a tremendous marketing boost for Glaxo before an ideally targeted audience. Glaxo manufactures two major AIDS-treatment drugs, including AZT, the first approved AIDS treatment, and has others awaiting regulatory approval; the company's annual sales of AIDS-treatment drugs amount to nearly $500 million. Glaxo is now engaged in what a company executive called a "market war" with Bristol-Myers Squibb for AIDS-treatment remedies.
For the rest of the weeklong conference, USA Today'smedical reporter, Steve Sternberg, had to endure colleagues and sources thrusting the "newspaper" at him and asking him whether his paper had sold out.
The paper maintains that it hasn't, partly because USA Todaygives away such promotional editions as a "value-added" premium to any company that commits to an undisclosed level of advertising.
USA Today has provided this service "a couple of hundred times" since 1982 for a wide variety of advertisers, newspaper spokesperson Anderson explains. According to Glaxo, USA Todaybrought them at least three other special editions--produced for Philips Lighting, Disney World, and a cruise-ship line--to entice the drug company to go with the idea.
Glaxo didn't need much coaxing. "It's a very innovative tool that USA Todayhas come up with," says Glaxo's Dark. Would Glaxo use it again? "Yes."
Tailoring a special edition for a single advertiser smashes the wall between editorial and advertising departments that most quality American newspapers strive to preserve. The fact that USA Todayhas repeatedly created these promotional editions "makes this all the more alarming," says Roberts. "It does not seem to be a case of the ad department raging out of control in a single case and not informing anyone, but rather it seems to be a definite practice--and it's a bad practice."
Roberts says that once the wall is down "and the advertising people have been told they can sell something, you just have a devil of a time in the newsroom trying to reverse that practice. And basically only the highest level of a newspaper or corporation can do it."
USA Today's Anderson counters that the circulation of the special editions "is very carefully controlled, and we feel we're not confusing anyone out there."
While journalists are apt to blame USA Today--after all, an advertiser would be foolish to refuse a free, mock edition of a national newspaper--AIDS activists weren't about to let Glaxo escape. Longtime San Francisco activist Martin Delaney fumes: "I've long argued against direct-to-consumer pharmaceutical advertising, and this takes it to a new level. Both Glaxo and USA Todayshould be horribly ashamed of themselves. The only possible objective of doing what they did was to deceive the reader. What other point could there be?"
The credibility problem USA Today has created for itself extends beyond its AIDS coverage. Earlier this year, Glaxo was rumored to be in merger talks with Smith Kline Beecham--business coverage of any such deals is now tainted by having rented the paper's logo to a company it's supposed to cover.
USA Today sources say that few members of the editorial staff were aware of the Glaxo arrangement prior to its being published, and several were displeased once they learned of it.
"Nobody here thinks this is a good idea," says a longtime USA Today reporter who asked not to be identified. "We've worked hard to shed the 'McPaper' reputation, and this sort of thing makes us look like we'll do anything for an ad."
As the New York Post's Page Six noted last week, a nasty accusation greeted David Remnick upon his ascension to the The New Yorker's top editorial position. A New York magazine Intelligencer item from 1993 has resurfaced in some journalistic circles; it accuses Remnick of having lifted material without attribution from a scholarly book for a December, 1992 New Yorker article Remnick wrote on Crown Heights.
This mini scandal is unlikely to affect Remnick, however, because the book's author is deceased.
Back in '93, New York reported that The New Yorker offered to give Mintz's book a favorable review--which could be interpreted as an indication of guilt.
But then-editor Tina Brown scoffed at the notion five years ago, a denial Remnick repeated this week in a Voice interview. Remnick recalled that, at the time, Mintz had written him "an aggrieved personal letter," to which he responded immediately. He had used the book, among "seven or eight or nine books" about messianic thought. Remnick insists, however, that his article "was not in any way plagiarism."
The matter was soon dropped, and no one--save whoever is faxing the old gossip item around--seems to want to keep it alive. When contacted this week by the Voice, Harvard University Press, which published Mintz's book, refused any comment.
Most important, the charge itself is thin. The original gossip item cited a single anonymous source, and did not point to any specific material deemed to have been lifted. A Voice comparison of the book and the Remnick article found some shared sections; most of that, however, was boilerplate material that both writers probably obtained from newspaper articles and official reports.
Remnick calls the incident "embarrassing," and though he felt he used other interpretations more than Mintz's, he agreed that "if I had it to do over, I would probably have nodded in the direction of Mintz and other scholars I leaned on." He says that in subsequent pieces--such as his recent article on the Amish--he has been attentive to citing other authors' work.
Research: Leila Abboud